Fig. 2: Relative changes from baseline in MRI-PDFF and cT1 relaxation time at week 12 for TERN-501 monotherapy groups (efficacy analysis set). | Nature Medicine

Fig. 2: Relative changes from baseline in MRI-PDFF and cT1 relaxation time at week 12 for TERN-501 monotherapy groups (efficacy analysis set).

From: TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trial

Fig. 2

a,b, Relative change from baseline in MRI-PDFF (a, placebo, n = 21; TERN-501 1 mg, n = 23 (P = 0.1303); TERN-501 3 mg, n = 19 (P = 0.0036); TERN-501 6 mg, n = 18 (P < 0.0001)) and cT1 relaxation time (b, placebo, n = 21; TERN-501 1 mg, n = 22 (P = 0.1289); TERN-501 3 mg, n = 19 (P = 0.1790); TERN-501 6 mg, n = 18 (P = 0.0008) at week 12 for TERN-501 monotherapy groups. Statistical analysis was performed using a type III sum of squares ANCOVA model with treatment group as a fixed effect and baseline value as the covariate; comparison between groups was conducted at the two-sided, 0.05 level of significance. No adjustments for multiplicity were made. **P < 0.01; ***P < 0.001 for TERN-501 monotherapy versus placebo. Error bars, s.e.

Source data

Back to article page